Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-s5ss2 Total loading time: 0.525 Render date: 2021-02-26T19:41:12.050Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives

Published online by Cambridge University Press:  01 January 2021

Extract

The ability to sustain antibiotic efficacy is directly affected by incentive models aiming to stimulate antibiotic research and development. This paper analyzes the extent to which the models proposed by the Innovative Medicine Initiative-funded research project DRIVE-AB can be expected to support sustainable use, drawing on basic economic theory and the incentives that derive from it. It then discusses the use of minimal safeguards that will be needed to support sustainable use where industry incentives have not been re-aligned with those of public health.

Type
Symposium Articles
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below.

References

DRIVE-AB, available at <http://drive-ab.eu/> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at <http://www.imi.europa.eu/projects-results/project-factsheets/drive-ab> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
See DRIVE-AB Final Report, supra note 2, at 15.Google Scholar
Essential Medicines and Health Products Information Portal, “Promoting Rational Use of Medicines: Core Components-WHO Policy Perspectives on Medicines,” No. 005, September 2002, available at <http://apps.who.int/medicinedocs/en/d/Jh3011e/> (last visited March 31, 2018); WHO, WHO Global Strategy for Containment of Antimicrobial Resistance, 2001, available at <http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018);+WHO,+WHO+Global+Strategy+for+Containment+of+Antimicrobial+Resistance,+2001,+available+at++(last+visited+March+31,+2018).>Google Scholar
Outterson, K., Gopinathan, U., Clift, C., So, A., Morel, C., and Røttingen, J. A., “Delinking Investment in Antibiotic R&D from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality,” PloS Medicine 13, no. 6 (2016): e1002043; C. Clift, U. Gopinathan, C. Morel, K. Outterson, J. A. Røttingen, and A. So, ‘Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales,” 2015, Chatham House, available at <https://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf> (last visited March 31, 2018); J. O'Neill, Securing New Drugs for Future Generations: The Pipeline of Antibiotics — The Review on Antimicrobial Resistance (2015), available at <https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf> (last visited March 31, 2018); J. Rex, and K. Outterson, “Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach,” The Lancet Infectious Diseases 16, no. 4 (2016): 500–505.Google Scholar
Norris, P., Herxheimer, A., Lexchin, J., and Mansfield, P., “Drug Promotion: What We Know, What We Have Yet to Learn: Reviews of Materials in the WHO/HAI Database on Drug Promotion,” WHO, 2005, available at <http://apps.who.int/iris/bitstream/10665/69177/1/WHO_EDM_PAR_2004.3_eng.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewn, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., Möller, H., Moucheraud, C., Pécoul, B., Rägo, L., Rashidian, A., Ross-Degnan, D., Stephens, P. N., Teerawattananon, Y., ‘t Hoen, E. F., Wagner, A. K., Yadav, P., and Reich, M. R., “Essential Medicines for Universal Health Coverage,” The Lancet 389, no. 10067 (2017): 403476.CrossRefGoogle Scholar
See DRIVE-AB Final Report, supra note 2.Google Scholar
Pulcini, C., Morel, C. M, Tacconelli, E., Beovic, B., de With, K., Goossens, H., Harbarth, S., Holmes, A., Howard, P., Morris, A. M., Nathwani, D., Sharland, M., Schouten, J., Thursky, K., Laxminarayan, R., and Mendelson, M., “Human Resources Estimates and Funding for Antibiotic Stewardship Teams Are Urgently Needed,” Clinical Microbiology and Infection 23, no. 11 (2017): 785787.Google Scholar
Global Drug Facility of the Stop TB partnership, available at <http://www.stoptb.org/gdf/> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Savic, M. and Årdal, C., “A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 924.Google Scholar
Baraldi, E., Lindahl, O., Savic, M., Findlay, D., and Årdal, C., “Antibiotic Pipeline Coordinators,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 2531.CrossRefGoogle Scholar
European Commission Global Health Policy Forum, access case study from DNDi, 2016, available at <https://ec.europa.eu/research/health/pdf/hpforum/3_ghpforum_brussels_2016-12_dndi_casestudies.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Sagal, M. W., Slowinski, G., Freese, K., and Ferguson, S., “Intellectual Property and Other Contractual Issues in Cooperative Research and Development Agreements (CRADAs): Part I,” Licensing Executives Society Nouvelles 44, no. 1 (2009): 4148.Google Scholar
See DRIVE-AB Final Report, supra note 2, at 55-57.Google Scholar

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 2
Total number of PDF views: 1 *
View data table for this chart

* Views captured on Cambridge Core between 01st January 2021 - 26th February 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *